Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Gufic Biosciences Ltd (GUFICBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 509079 NSE: GUFICBIO Pharmaceuticals & Drugs | Small Cap | Gufic Biosciences Share Price

₹422.90 1.65 (0.39%)

As on 25-Sep'26 16:59

Gufic Biosciences Ltd (GUFICBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 509079 NSE: GUFICBIO Pharmaceuticals & Drugs | Small Cap | Gufic Biosciences Share Price

₹422.90 1.65 (0.39%)

As on 25-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹4,241 Cr.
Current Price
₹422.9
52-Week Low / High
₹268 / 466
TTM EPS
₹7.3
TTM Sales
₹981 Cr.
Book Value per Share
₹68.5
P/E Ratio
57.73
Higher than its 5-year historical median
Industry PE
54.9
Price to Book (P/B)
6.17
Lower than its 5-year historical median
Price to Sales (P/S)
4.32
Higher than its 5-year historical median
EV/EBITDA
27.27
Higher than its 5-year historical median
Dividend Yield
0.02%
Profitability Efficiency
Return on Equity (ROE)
10.14%
Outperforms industry median
Return on Capital Employed (ROCE)
12.56%
Outperforms industry median
Return on Assets (ROA)
5.11%
Operating Profit Margin
16%
Net Profit Margin
6.8%
Gross Profit Margin
9.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
14.72%
Operating Profit Growth (1 Year)
-
11.2%
Net Profit Growth (1 Year)
-
-7.81%
Asset Quality
Promoter Holding
72.50%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹677 Cr.
Equity
₹10 Cr.
Face Value
₹1
All Time Low / High
₹0.17 / 501.10

Gufic Biosciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Gufic Biosciences Ltd a good quality company?
Gufic Biosciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Gufic Biosciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Gufic Biosciences Ltd vs industry peers?
Gufic Biosciences Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Q.1 Promoter shareholding and pledge status of Gufic Biosciences Ltd?
Promoters hold 72.50% of the Gufic Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Gufic Biosciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 27.4% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gufic Biosciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ24.3%34.1%29.7%21%30.1%47.3%23.2%17.6%13.5%12.5%-
Value Creation
Index ⓘ		0.71.41.10.51.22.40.70.30.0-0.1-

Growth Parameters ⓘ
Sales ⓘ246306351379488779691807820940974
Sales YoY Gr.-24.5%14.8%8%28.7%59.8%-11.4%16.8%1.6%14.7%-
Adj EPS ⓘ1.11.92.82.44.59.88.48.77.16.37.3
YoY Gr.-74.8%43.3%-15.1%89%120.4%-14.2%3.4%-18.2%-12.1%-
BVPS (₹) ⓘ4.879.713.317.927.835.953.16066.268.5
Adj Net
Profit ⓘ		8.615.121.722.943.295.381.887.471.562.974
Cash Flow from Ops. ⓘ-4.1-4.85.247.187.3106-26.6-7.512344.2-
Debt/CF from Ops. ⓘ-13.7-16.518.82.50.60.6-11.7-42.52.58.7-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ16.1%14%10.8%14.7%
Adj EPS ⓘ21.2%7.1%-9.4%-12.1%
BVPSⓘ33.8%29.9%22.7%10.5%
Share Price 27.5% 16.7% 13.7% 18.4%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		24.23333.522.328.543.126.519.912.69.910.9
Op. Profit
Mgn % ⓘ		9.412.713.113.817.21919.918.616.91616.9
Net Profit
Mgn % ⓘ		3.54.96.268.912.211.810.88.76.77.6
Debt to
Equity ⓘ		1.51.51.30.90.30.20.90.60.50.6-
Working Cap
Days ⓘ		190201239254201136187213203204142
Cash Conv.
Cycle ⓘ		6786738447315591838950

Valuation of Gufic Biosciences - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'24Mar'25Mar'26
Sales807820944
Operating Expenses ⓘ + 659684793
Manufacturing Costs107125167
Material Costs339310349
Employee Cost 110127152
Other Costs ⓘ 103122125
Operating Profit ⓘ 147136151
Operating Profit Margin (%) 18.3%16.6%16.0%
Other Income ⓘ + 243
Exceptional Items ⓘ 000
Interest ⓘ 172537
Depreciation ⓘ 172131
Profit Before Tax ⓘ 1169487
Tax ⓘ 302422
Profit After Tax 867064
PAT Margin (%) 10.7%8.5%6.8%
Adjusted EPS (₹)8.67.06.4
Dividend Payout Ratio (%)1.20%1.40%1.60%
PARTICULARSMar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 533601665
Share Capital ⓘ 10.0310.0310.03
Reserves ⓘ 523591655
Debt +296285359
Long Term Debt154130105
Short Term Debt142154254
Minority Interest000
Trade Payables166159199
Others Liabilities ⓘ 98125119
Total Liabilities ⓘ 1,0931,1691,342

Fixed Assets

Net Fixed Assets ⓘ +159506491
Gross Block246614630
Accumulated Depreciation87108139
CWIP ⓘ 3072222
Investments ⓘ 222
Inventories200217324
Trade Receivables330315297
Cash Equivalents 132976
Others Assets ⓘ 8179129
Total Assets ⓘ 1,0931,1691,342
PARTICULARSMar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + -712345
PBT ⓘ 1169487
Adjustment ⓘ 344465
Changes in Working Capital ⓘ -1307-95
Tax Paid ⓘ -27-23-12
Cash Flow From Investing Activity ⓘ + -102-71-31
Capex -108-71-31
Net Investments -10-0
Others ⓘ 7-00
Cash Flow From Financing Activity ⓘ + 82-3732
Net Proceeds from Shares ⓘ 10000
Net Proceeds from Borrowing ⓘ -37-24-25
Interest Paid ⓘ -13-23-35
Dividend Paid ⓘ -1-1-1
Others ⓘ 331094
Net Cash Flow ⓘ -271546
PARTICULARSMar'24Mar'25Mar'26
Ratios
ROE (%)16.1712.2910.14
ROCE (%)15.5913.4812.56
Asset Turnover Ratio0.860.970.97
PAT to CFO Conversion(x)-0.081.760.7
Working Capital Days
Receivable Days128.10106.9091.40
Inventory Days77.8069.2080.80
Payable Days179191.40187.10

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gufic Biosciences Ltd FAQs

The current trading price of Gufic Biosciences on 25-Sep-2026 16:59 is ₹422.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of Gufic Biosciences stood at ₹4,241 Cr

The latest P/E ratio of Gufic Biosciences as of 24-Sep-2026 is 57.67.

The latest P/B ratio of Gufic Biosciences as of 24-Sep-2026 is 6.18.

The 52-week high of Gufic Biosciences is ₹466.1 and the 52-week low is ₹267.5.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gufic Biosciences is ₹974 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gufic Biosciences Ltd is a below average quality company.

The key valuation ratios of Gufic Biosciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Gufic Biosciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Gufic Biosciences Ltd

The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

  • Pharmaceutical
  • Herbal
  • API / Bulk Drugs
  • Personal care
  • International

History and milestone

Past Initiatives

  • First Indian to produce Doxycycline Inj.
  • First Indian company to make Liquid Oxytetracycline Inj.
  • Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
  • First Company to launch Boswellia Serrata tablets
  • Pioneer in developing Kid tablet in India
  • Hived off Mox and Zole to Ranbaxy

2007-2009

  • Initiated contract manufacturing
  • Commenced international exports

2010-2015

  • Received patents for Anidulafungin and Tigecycline lyophilized inj.
  • Launched Criticare division

2016

  • Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
  • Launched Ferticare and Criticare Life divisions

2017-2019

  • Received patents for Rifabutin and Micafunginlyophilized inj.
  • Exported Vancomycin lyophilized Inj. to Germany
  • Manufacturing capacity ramped up to 31 million vials per annum
  • Launched Ferticare Life division

2020

  • Manufacturing Remdesivir for Hetero
  • Increased capacity to 48 million vials per annum

2022

  • Incorporated wholly owned subsidiary company namely ‘Gufic UK’
  • Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now